Idiopathic pulmonary fibrosis;Idiopatická plicní fibróza

Vnitrni Lekarstvi

Volumn 51, Issue 12, 2005, Pages 1375-1384

  Doubková, Martina ^a   Skrickova J ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Fibrogenesis; Idiopathic interstitial pneumonia; Pulmonary fibrosis; Treatment

Indexed keywords

CONSERVATIVE TREATMENT; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROGENESIS; FIBROSING ALVEOLITIS; INFLAMMATION; INTERSTITIAL PNEUMONIA; LUNG FIBROSIS; LUNG PARENCHYMA; LUNG TRANSPLANTATION; MYOFIBROBLAST; RESPIRATORY FAILURE; REVIEW;

HUMANS; PULMONARY FIBROSIS;

EID: 29544441073     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. American Thoracic Society/European Respiratory Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000; 161: 646-664.
2. American Thoracic Society/European Respiratory Society: International multidisciplinary consensus classification of the idiopathic intersticial pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
3. Antoniou KM, Ferdoutsis E, Bouros D et al. Interferons and their application in the lung. Chest 2003; 123: 209-216.
4. Bourke SC, Clague H. Review of cryptogenic fibrosing alveolitis, including current treatment guidelines. Postgrad Med J 2000; 76: 618-624.
5. Coultas DB, Zumwalt RE, Black WC et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967-972.
6. Crystal RG, Bitterman PB, Mossman B et al. Future research directions in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 166: 236-246.
7. Cushley M, Davidson A, Du Bois R et al. Diagnosis and assessment of diffuse parenchymal lung disease. Thorax 1999; 54(Suppl): 1-30.
8. Davies HR, Richeldi L. Idiopathic pulmonary fibrosis: current and future treatment options. Am J Respir Med 2002; 1: 211-224.
9. Davies HR, Richeldi L, Walters EH et al. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003; 3: CD003134.
10. Demedts M, du Bois RM, Nemery B et al. Interstitical lung diseases: a clinical update. Eur Respir J 2001; 18: 1S-133S.
11. Dunsmore SE, Shapiro SD The bone marrow leaves its scar: new concepts in pulmonary fibrosis. J Clin Invest 2004; 113: 180-182.
12. Fiserova J, Chlumský J, Satinská J et al. Funkční vyšetřeni plie. GEUM, Praha, 2003.
13. Flaherty KR, Colby TV, Travis WD et al. Fibroblastic foci in usual interstitial pneumonia. Am J Respir Crit Care Med 2003; 167: 1410-1415.
14. Flaherty KR, Thwaite EL, Kazeorooni EA et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003; 58: 143-148.
15. Flaherty KR, Toews GB, Lynch III JP et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001; 110: 278-282.
16. Gazdik F, Zubo I, Gazdikovâ K. Imunologické mechanizmy při vybraných intersticiálnych pl'úcnych procesoch. Stud Pneumol Phthiseol 2003; 63: 199-207.
17. Green FHY. Overview of pulmonary fibrosis. Chest 2002; 122: 334S-339S.
18. Hamman L, Rich AR. A clinicalpathological conference. A case of heart failure. International Clinics., 43rd series, 1933, 1: 197-232.
19. Hamman L, Rich AR Fulminant diffuse interstitial fibrosis of the lungs. Trans Am Clin Climatol Assoc 1935; 51: 154-163.
20. Hamman L, Rich AR. Acute difuse interstitial fibrosis of the lung. Bull. Johns Hopkins Hosp 1944; 74: 177-212.
21. Hanáček J. Patofyziológia intersticiálnych pl'úcných chorob. Stud Pneumol Phthiseol 1999; 59: 246-254.
22. Homolka J, Altmann V, Votava V. Increasing prevalence of idiopatic pulmonary fibrosis in the Czech Republic. Chest 1999; 116(Suppl. 2): 155.
23. Homolka J, Votava V. Intersticialni plicní procesy. Praha: Maxdorf 1999.
24. Ionaga K, Miyajima M, Suga M et al. Alteration in cytokeratin expression by the alveolar lining epithelial cells lung tissues from patients with idiopathic pulmonary fibrosis. J Pathol 1997; 182: 217-224.
25. Kaminski N, Belperio JA, Bitterman PB et al. Idiopathic pulmonary fibrosis, suplement. Am J Respir Cell Mol Biol 2003; 29: 1S-105S.
26. Katzenstein AA, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157: 1301-1315.
27. Khahil N, O'Connor R Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment. Can Med Assoc J 2004; 171: 153-160.
28. Kolek V. Epidemiology of cryptogenic fibrosing alveolitis in Moravia and Silesia in the 1981-1990. L'internista 1995; 3: 105-108.
29. Kolek V. Diagnostika a léčba idiopatických intersticiálních pneumonií. Respirace 2001; 7: 98-104.
30. Kolek V, Lenhart K, Bártová A. Imunogenetické aspekty kryptogenní fibrotizující alveolitidy. Stud Pneumol Phthiseol 1997; 57: 104-105.
31. Kolek V, Žurková M, Petřek M et al. Klinické zkušenosti s idiopatickou plicní fibrózou ve vztahu k nové klasifikaci. Stud Pneumol Phthiseol 2000; 60: 168-170.
32. Kotton DN, Ma BY, Cardoso WV et al. Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 2001; 128: 5181-5188.
33. Kuhn C, McDonald JA The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastruktural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991; 138: 1257-1265.
34. Levinsky L, Houštěk J, Hloušková Z et al. Prevalence idiopatické difusní intersticiální plicní fibrosy v ČSSR (Československu). Česk Pediatr 1974; 29: 353-357.
35. Liebow A. Definition and classification of interstitial pneumonias in human pathology. Prog Resp Res 1975; 8: 1-33.
36. Marshall RP, Puddicombe A, Cookson WO et al. Adult familial cryptogenic fibrosing alveolitis in United Kingdom. Thorax 2000; 55: 143-146.
37. Meyers BF, Lynch JP, Turlock EP et al. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-yer institutional experience. J Thorax Cardiovsc Surg 2000; 120: 99-107.
38. Millar A. Anti-cytokine therapy in fibrosing alveolitis: where are we now? Respir Res 2000; 1: 3-5.
39. Nicholson AG, Colgy TV, du Bois RM et al. The prognostic significance of the histologie pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing. Am J Respir Crit Care Med 2000; 162: 2213-2217.
40. Panos RJ, Morrenson RL, Niccoli SA et al. Clinical deterioration in patiens with idiopathic pulmonary fibrosis: cause and assessment. Am J Med 1990; 88: 396-404.
41. Polák J, Homolka J, Vašáková M et al. High-resolution počitačová tomografie v diagnostice kryptogenní fibrotizující alveolitidy. Koreiace s plicnim funkčním vyšetřením a bronchoalveolá rní laváží. Cas Lék Česk 1996; 135: 417-422.
42. Raghu G, Brown KK, Bradford WZ et al. A placebo-controlled trial of interfere n gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-133.
43. Ramos C, Montano M, Garcia-Alvarez J et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growt rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 2001; 24: 591-598.
44. Reynolds HY, Newball HH Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J Lab Clin Med 1974; 84: 559-573.
45. Richeldi L, Davies HR, Ferrara G et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2004; 4: CD002880.
46. Sandoz E. Über zwei Fälle von "fötaler Bronchektasie". Thesis (doctoral). Bern: Universität Bern 1906.
47. Satinská J. Význam funkčniho vyšetř ování u chronické obstrukční plicní nemoci. Vnitř Lék 2004; 50: 670-674.
48. Selman M, King TE, Pardo A et al. Idiopathic pulmonary fibrosis: prevailing a evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-151.
49. Selman M, Thannickal VJ, Pardo A et al. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 2004; 64: 405-430.
50. Skřičková J. Diferenciální diagnostika pneumonií z pohledu klinika. In: Ševčík P, Skřičková J, Šrámek V et al. Záněty plic v intenzivní medicíně. Praha: Galén 2004: 49-59.
51. Strieter RM, Starko KM, Enelow RI et al. Effects of interferon-1b on biomarker expression in patients with idiopathic pulmoary fibrosis. AmJ Respir Crit Care Med 2004; 170: 133-140.
52. Turner-Warwick M, Burrows B, Johson A et al. Cryptogenic fibrosin alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 1980; 35: 593-599.
53. Uhal BD, Joshi I, True AL et al. Fibroblasts isolated after fibrotic lung injury induce apoptosisi of alveolar epithelial cells in vitro. Am J Physiol 1995; 269: L819-L828.
54. Vašákovâ M. Idiopatická plicní fibróza (kryptogenní fibrotizující alveolitida). In: Zatloukal P, Fiala P, Votruba J et al. Vnitřní lékařství. Díl IIIa. Pneumologie. Praha: Galén 2001: 145-149.
55. Votava V, Svobodová L, Homolka J. Intersticiální plicní procesy (přehledný článek). Čas Lék Čes 2002; 141: 445-448.
56. Vyšehradský R, Farmakoterapia kryptogénnej fibrotizujúcej alveolitidy. Stud Pneumol Phthiseol 2001; 61: 195-198.
57. Walker GA, Guerrero IA, Leinwand LA et al. Myofibroblasts: molecular crosscressers. Curr Top Dev Biol 2001; 51: 91-107.
58. Wang R, Ramos C, Joshi I et al. Human lung myofibrobalst-derived inducers of alveolar eppithelial apoptosis identified as angiotensin peptides. Am J Physiol 1999; 277: L11S8-L1164.
59. White ES, Lazar MH, Thanmckal VJ. Pathogenetic mechanism in usual interstitial pneumonia/idiopathic pulmonary fibrosis. J Pathol 2003; 201: 343-354.